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Contraceptive Provision to
Adolescent Females Prescribed
Teratogenic Medications
Stephani L. Stancil, MS, FNP-BC,a,b Melissa Miller, MD,c,d Holley Briggs, DO,e Daryl
Lynch, MD,a,d Kathy Goggin, PhD,d,f,g Gregory Kearns, PharmD, PhDb,h,i

BACKGROUND AND OBJECTIVES: Rates of adult women receiving contraceptive provision when

abstract

simultaneously prescribed a known teratogen are alarmingly low. The prevalence of
this behavior among pediatric providers and their adolescent patients is unknown. The
objective of this study was to describe pediatric provider behaviors for prescribing
teratogens concurrently with counseling, referral, and/or prescribing of contraception
(collectively called contraceptive provision) in the adolescent population.
METHODS: A retrospective review was conducted examining visits in 2008–2012 by

adolescents aged 14 to 25 years in which a known teratogen (US Food and Drug
Administration pregnancy risk category D or X) was prescribed. The electronic medical
records were queried for demographic information, evidence of contraceptive provision,
and menstrual and sexual histories. The data were analyzed using standard statistical
methods.
RESULTS: Within 4172 clinic visits, 1694 females received 4506 prescriptions for teratogenic

medications. The most commonly prescribed teratogens were topiramate, methotrexate,
diazepam, isotretinoin, and enalapril. The subspecialties prescribing teratogens most
frequently were neurology, hematology-oncology, and dermatology. Overall, contraceptive
provision was documented in 28.6% of the visits. Whites versus nonwhites and older versus
younger girls were more likely to receive contraceptive provision. The presence of a federal
risk mitigation system for the teratogen also increased the likelihood of contraceptive
provision.
CONCLUSIONS: Our data demonstrate female adolescents prescribed teratogens receive

inadequate contraception provision, which could increase their risk for negative pregnancy
outcomes. Although the presence of a federal risk mitigation system appears to improve
contraceptive provision, these systems are costly and, in some instances, difficult to
implement. Efforts to improve provider practices are needed.
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WHAT’S KNOWN ON THIS SUBJECT: Adolescents in the United States
have high rates of unintended pregnancy and may be prescribed
medicines of teratogenic potential. The frequency of reproductive
health counseling by pediatric providers to female adolescents
prescribed these medications isnot known.
WHAT THIS STUDY ADDS: Adolescents prescribed known teratogens
are receiving suboptimal reproductive health care. Our data
illustrate that provider interventions must focus not only on sexual
behaviors and the need for contraceptive care but also should
include education regarding teratogenic risk associated with
treatment.

To cite: Stancil SL, Miller M, Briggs H, et al. Contraceptive
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Medications. Pediatrics. 2016;137(1):e20151454
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TABLE 1 Teratogenic Medications Queried for During Study Period
albendazole
alprazolam
amiodarone
atenolol
atorvastatin
azathioprine
bosentan
captopril
carbamazepine
clonazepam
cyclophosphamide
dasatinib
diazepam
divalproex sodium
efavirenz

enalapril
etoposide
ﬂuconazole
ﬂuvastatin
griseofulvin
imatinib
irinotecan
isotretinoin
itraconazole
leﬂunomide
letrozole
lisinopril
lithium
lomustine
lorazepam

losartan
lovastatin
megestrol
mercaptopurine
methimazole
methotrexate
misoprostol
mycophenolate acid
mycophenolate mofetil
paroxetine
penicillamine
phenytoin
pitavastatin
pravastatin
ribavirin

rosuvastatin
simvastatin
sirolimus
spironolactone
tazarotene
temozolomide
tetracycles
thalidomide
thioguanine
topiramate
topotecan
valproic acid
voriconazole
warfarin

All medications listed were queried in females. Thalidomide was the only medication queried in males.

Limited data are available regarding
prescribing of contraception
to adolescents who have been
concurrently prescribed a drug
with known teratogenic potential
(ie, teratogens). To communicate
the potential teratogenic risk of a
medication to the prescriber, the US
Food and Drug Administration (FDA)
currently uses an evidence-based
grading system as part of product
labeling that categorizes medications
by potential for teratogenic risk
(eg, category A are those with no
demonstrated risk, categories D and
X are those associated with definite
risk and positive evidence of fetal
harm).1
Several studies of family and internal
medicine providers demonstrated low
rates (20%–48%) of contraception
provision among females of
reproductive age prescribed
teratogens.1–4 However, no previous
study has evaluated practices among
pediatric providers or examined rates
of documentation of sexual history
or menstrual history in adolescents
prescribed teratogens. To address
this knowledge gap, we conducted a
targeted, retrospective assessment
of contraception provision in a
large cohort of adolescent females
prescribed potential teratogens.

METHODS
Study Design
A single-center, retrospective audit
of data available in the electronic
medical record (EMR) was conducted
at a large Midwestern academic
pediatric medical center. The
study was approved by hospital
institutional review board and
was determined to be exempt
from informed consent or assent
requirements.

Selection of Participants
EMR data from female patients
aged 14 to 25 years who were
prescribed a known teratogen at
hospital discharge or as an outpatient
between January 1, 2008, and
December 31, 2012, were included
in this study. A total of 59 drugs
labeled by the FDA as pregnancy
risk categories D or X comprised the
drug list (see Table 1). This list is not
inclusive of all medications labeled
as Category D or X by the FDA but
rather a select group chosen based
on preliminary inquiry of high-risk
medications commonly prescribed
at the pediatric medical center.
Data from male patients aged 14
to 25 years who were prescribed
thalidomide (a drug with paternal
reproductive health guidance issued
by the manufacturer to reduce
teratogenic risk)5,6 were also eligible
for inclusion. Data were excluded
from patients in whom the teratogen

was prescribed for inpatient use only,
as were those for patients prescribed
a single dose of fluconazole for
treatment of vulvovaginitis. Data
from patients receiving fluconazole
for >1 day were included in the
analysis.

Data Collection and Outcome
Measures
Encounters during which a
teratogen was prescribed were
queried for any documentation
of contraceptive counsel (via key
word search described later in the
article or International Classification
of Diseases, 9th Revision, codes
V25.xx or V45.5), contraceptive
prescription (via order indicating
new prescription or documentation
in medication list indicating
prescription at previous visit) or
referral for contraceptive care
(via key terms search or order
available in EMR). The pediatric
specialty responsible for teratogenic
prescription was also denoted
(nephrology, hematology-oncology,
etc.). Documentation of sexual
history and menstrual history was
determined based on key term
search. Demographic data (age,
gender, race, insurance status) were
also recorded for each encounter
during which a teratogen was
prescribed. Separate analyses were
performed on medications associated
with formal federal surveillance
programs, such as iPLEDGE and Risk
Evaluation and Mitigation Strategy
(REMS). These systems are used
by the FDA when additional safety
measures are needed beyond the
professional labeling to ensure
benefits of the medication outweigh
risks, particularly with documented
evidence of severe birth defects
(ie, teratogenicity).7 On the basis
the assessment of risk completed
by the FDA and agreement with
manufacturer, there are various
methods employed when a REMS
is put into place, including, but
not limited to, letters sent to
prescribers, training requirements
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TABLE 2 Terms Used in Automated Key Term Search
Contraceptive Counsel
contraception
contraceptive
condom
birth control
abstinence
barrier protection
LARC
Plan B
emergency contraception
emergency contraceptive
OCP
Implant
NuvaRing
Nexplanon
Implanon
Mirena
IUD
Depo Provera

Contraceptive Referral
refer for contraception
refer for birth control
follow up for contraception
follow up for birth control
refer to OBGYN
follow up with OBGYN
refer for Depo-Provera
refer for contraceptive
follow up for contraceptive
refer for discussion of birth
control
refer for Depo-Provera
refer for OCP
refer for IUD
refer for NuvaRing
refer for Nexplanon
refer for Implanon
refer for Implant
follow up for discussion of
birth control
follow up for Depo-Provera
follow up for OCP
follow up for IUD
follow up for NuvaRing
follow up for Nexplanon
follow up for Implanon
follow up for Implant

Sexual History
sex
vaginal
sexually active
sexual activity
intercourse
coitus
coitarche
same sex
homosexual

Menstrual History
menarche
menses
last menstrual period
LMP

IUD, intrauterine device; LMP, last menstrual period; OCP, oral contraceptive pills.

for prescribers, and information
disseminated via professional
organizations.
To facilitate EMR review, we created
a list of key terms and performed
an automated EMR search via
full text index for these terms to
identify contraception provision
and sexual/menstrual histories.
The list (Table 2) was developed
by an multidisciplinary team of
content experts and was intended
to capture terms that would affirm
documentation of contraceptive
counsel, referral, sexual history, or
menstrual history while optimizing
efficiency of a large retrospective
review. If ≥1 key terms were found
within the documents specific to
the encounter during which the
teratogen was prescribed, the
encounter was deemed to have
documentation of the respective
outcome measure (contraceptive
counsel, referral, sexual history, or
menstrual history). To validate the
novel automated key term search

strategy, we randomly selected 200
encounters from the original 4172
and performed a manual review of
the EMR to serve as the reference
standard. One author reviewed
each of 200 encounters followed
by review by a second author. Any
discrepancies were resolved by
consensus between these 2 authors.
This subset size was chosen to limit
manual annotation burden while
ensuring a robust sample size for
comparison of the automated key
term search strategy with manual
review. We determined sensitivity,
specificity, positive predictive value,
and negative predictive value along
with 95% confidence intervals (CIs)
to access validity of the automated
search strategy.

Data Analysis
Data were analyzed by using Excel
2007 (Microsoft Corporation,
Redmond, WA) and SPSS Statistics
version 20 (IBM Corporation,
Armonk, NY) to inform standard

statistical measures along with
OpenEpi and Vasserstats.8,9 χ2 test
was used to evaluate comparisons
between groups (eg, contraceptive
provision documented in younger
vs older patients). Relative risk (RR)
assessment, including assessment
of 95% confidence limits, was
used to infer clinical significance
associated with key findings.
Multivariate regression analysis was
also completed to identify variables
that were predictive of receipt
of contraceptive provision. The
significance level set for all statistical
analyses was α = 0.05.

RESULTS
We identified 1694 female patients
aged 14 to 25 who received 4506
prescriptions for teratogenic
medications over the course of 4172
clinic visits (ie, encounters). No
males received a prescription for
thalidomide. The 5 most commonly
prescribed teratogens (in decreasing
frequency) were topiramate,
methotrexate, diazepam, isotretinoin,
and enalapril (see Fig 1). The 3
pediatric specialties prescribing
teratogens with highest frequency
were neurology, hematologyoncology, and dermatology (see
Fig 2). Contraceptive provision
was documented in 15.6%, 28.0%,
and 46.9% of their encounters,
respectively. Overall, contraceptive
provision (ie, counsel, prescription,
or referral) was documented in
1194 of 4172 (28.6%) encounters.
Prescriptions for contraception (or
documentation of current use) were
present in 11% of encounters.
Of the 1694 females, 74% were
white, 13% were black, and 7%
were Hispanic, followed by smaller
fractions of other ethnicities.
The mean age of the patients in
this study was 15.9 years (SD
1.6). Certain patient groups were
identified as being more likely to
receive contraceptive provision
compared with their peers: whites
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Teratogens Prescribed With Highest Frequency
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FIGURE 1
Twenty most commonly prescribed teratogens. Quantity indicates number of encounters during
which the teratogen was prescribed.

FIGURE 2
Pediatric specialty responsible for prescription of teratogen. Quantity indicates number of
encounters during which a teratogen was prescribed.

versus nonwhites (RR 1.61, 95%
CI, 1.41–1.83), older (≥16 years)
versus younger girls (14–15 years;
RR 1.20, 95% CI, 1.09–1.33), and
those with either Medicaid or no
insurance versus those with private
commercial insurance (RR 1.09, 95%
CI, 0.99–1.21). The presence of a
federal surveillance system for the
prescribed teratogen (eg, iPLEDGE
or REMS) increased the chances of
a patient receiving contraceptive
provision (RR 2.09, 95% CI, 1.88–
2.32). The presence of a federal
surveillance system for a prescribed
teratogen was associated with less
frequent documentation of menstrual
(RR 0.49, 95% CI, 0.37–0.69) and
sexual histories (RR 0.56, 95% CI,
0.43–0.74) at that visit. Prescribers
of teratogens were more likely to
document a sexual history in younger
girls compared with older girls (RR
1.34, 95% CI, 1.18–1.51). All of the
aforementioned comparisons were
statistically significant as determined
by χ2 tests (see Table 3). To identify
variables that were predictive of
receipt of contraceptive provision
while controlling for confounders,
multivariate regression analysis
was performed, and adjusted
odds ratios (aOR) were calculated.
Age ≥16 years, race, year of visit,
noncommercial insurance coverage
(Medicaid or no insurance), and
presence of REMS were all significant
predictors of receipt of contraceptive
provision (see Table 4).
The sensitivity, specificity, positive
predictive value, and negative
predictive value of the automated
key term search method for each
of the 4 categories are summarized
in Table 5. Overall, the automated
method performed well in all 4
categories with sensitivity ranging
from 88% to 100% and specificity
ranging from 90% to 100%. Two
terms appeared to explain the
majority of discrepancies identified
between the automated key term
search method and the manual
review. The term “implant” included
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in the contraceptive counsel key
term category was documented in
the context of a noncontraceptive
surgical implant, such as vagal nerve
stimulator “implant” or cardiac
pacemaker “implant.” The automated
key term search strategy found
“implant’ in 11 such cases (of 55
total positives found via automated
key term search) as affirmation of
contraceptive counsel due to the
nonspecific nature of this term.
Also, “sex” was a term listed in the
sexual history category that affirmed
documentation of sexual history in 8
cases (of 49 total positives found via
automated key term search) where
actual documentation was described
as simply sex at birth (ie, female or
male).

DISCUSSION
Previously published data reveal
that rates of women receiving
contraception counseling and/
or prescription who have been
prescribed a teratogen by an adult
care provider are alarmingly
low. One study of a family
practice resident clinic evaluated
contraceptive counseling provided
to women aged 15 to 44 years who
were also prescribed a teratogen
and found the rate of documented
contraceptive counseling to be
46%.4 This increased to 80% after
an educational intervention was
introduced. Another study evaluated
contraceptive counseling in women
of reproductive age prescribed drugs
in FDA categories A and B compared
with those in the D or X category.
The rates of contraceptive counseling
between the groups were similar, and
thus women in the study prescribed
a known teratogen were at increased
risk for fetal harm during pregnancy
compared with women prescribed
nonteratogenic medications.1 In
another study evaluating practices
of ambulatory care providers
prescribing potential teratogenic
drugs in women aged 14 to 44

TABLE 3 Descriptive Comparison Between Subgroups of Patients Prescribed a Teratogen (N = 4172
Encounters, Unless Otherwise Stated)
χ2

P

31.9% whites, 19.9% non whites

58.43

<.001

30.9% older, 25.7% younger

13.42

<.001

30.1% non-commercial, 27.6%
commercial

3.2

.037

53.7% REMS, 25.7% non-REMS

148.4

<.001

14.2% non-REMS, 6.9% REMS

17.4

<.001

19.7% non-REMS, 11.1% REMS

18.7

<.001

21.9% younger, 16.4% older

20.3

<.001

Comparison

Percentage

Contraceptive provision among whites vs
non-whites
Contraceptive provision among older (≥16 y)
vs younger (14–15 y)
Contraceptive provision among Medicaid or
no insurance vs commercial insurance N =
4159, 13 missing)
Contraceptive provision with presence of
federal risk mitigation system
Menstrual history with federal risk mitigation
system
Sexual history with federal risk mitigation
system
Sexual history among younger (14–15 y) vs
older (≥16 y)

TABLE 4 Variables Predictive of Contraceptive Provision
Variable
Age ≥16 y
Race (reference = white)
Black
Hispanic
Asian
Other
Year of visit (ascending)
Non-commercial Insurance
REMS

aOR (95% CI)

P

1.30 (1.13–1.50)

<.001

0.35 (0.28–0.45)
0.81 (0.60–1.10)
0.49 (0.23–1.10)
0.47 (0.33–0.67)
1.26 (1.18–1.33)
1.22 (1.05–1.42)
3.33 (2.69–4.11)

<.001
.17
.08
<.001
<.001
<.01
<.001

aOR, adjusted odds ratio.

TABLE 5 Data Validation of Automated Key Term Search Strategy
Category

Sensitivity (95%
CI)

Speciﬁcity (95%
CI)

PPV (95% CI)

NPV (95% CI)

Contraceptive counsel

98% (85%–
99.8%)
95% (82%–99%)
88% (69%–97%)

90% (84%–94%)

71% (57%–82%)

99% (96%–99.9%)

94% (88%–97%)
100% (97%–
100%)

80% (65%–89%)
100% (82%–
100%)

99% (95%–99.7%)
98% (95%–99.5%)

Sexual history
Menstrual history

Only 1 encounter met requirements for contraceptive referral by automated search method and manual review; agreement
was 100% between the methods; however, statistical analysis is limited because of the low prevalence of this condition.
PPV, positive predictive value; NPV, negative predictive value.

years, contraceptive counseling was
documented in only 20% of cases.2
Collectively, these previous studies
illustrate that women of reproductive
age who were prescribed a known
teratogen were no more likely to
receive contraceptive counseling
than women prescribed a medication
with low or absent teratogenic risk.
Our study underscores that this
missed opportunity for reproductive
health counseling extends to the
adolescent female population. Less

than one-third of our adolescent
cohort prescribed a teratogen had
documentation of contraceptive
provision. Of these patients, only
11% received or were currently
using some sort of prescribed
contraceptive medication or
device. Factors such as white
race and coverage by Medicaid
or no insurance were predictive
of contraceptive provision. This
evidence was demonstrated first by
χ2 analysis and strengthened after
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controlling for confounding variables
as described by multivariate analysis.
Year of visit was also predictive of
receipt of contraceptive provision. In
fact, each year after 2008 (beginning
of study period) conferred a 26%
increase in contraceptive provision
compared with preceding year. The
higher occurrence of contraceptive
provision in our older patients
(16–25 years) may have been driven
by a bias held by some pediatric
providers regarding a perceived low
incidence of sexual intercourse10–12
and, by inference, lower teratogenic
risk in younger girls (ie, 14–15
years). However, this assumption
is inconsistent with established
literature.
According to the National data
from the 2013 Youth Risk Behavior
Surveillance System, 35.2% of
adolescent females (grades 9–12,
typical age 14–18 years) were
classified as currently sexually active
(ie, having had sex in past 3 months),
and 15.7% of the these females
reported not using any method to
prevent pregnancy during their
more recent sexual encounter. Only
29.8% of these females reported
contraceptive (ie, birth control pills,
patch, ring, injection, IUD, or implant)
use, and 53.1% reported condom
use to prevent pregnancy before/
during their last sexual encounter.
Also, 28% of ninth graders (typical
age 14–15 years) and 41.7% of tenth
graders reported at least 1 episode of
sexual intercourse in their lifetime.13
This information highlights the
importance of recognizing the early
onset of sexual activity in young
females and the commensurate
increased risk for pregnancy and
poor fetal outcome when these
patients are prescribed a drug
with known teratogenic potential
absent their receiving appropriate
education/warning. Clearly, such
harm may be preventable through
prudent intervention by health care
providers and purposeful education
when medications with significant

teratogenic potential are prescribed.
Of note, our study did not specifically
evaluate the prevalence of sexually
active females in our adolescent
cohort but rather evaluated
whether a sexual history had been
documented by the provider (ie,
asking the question about history
of any previous sex regardless of
answer).
Many of the teratogenic medications
queried in this study are used
for treatment of chronic disease
states (eg, cyclophosphamide,
mycophenolate-containing products,
azathioprine, methotrexate for
immunosuppression; isotretinoin
for severe acne; topiramate for
chronic migraine prophylaxis).
Often, less teratogenic options may
not be available to the prescriber
or appropriate for the patient.
Therefore, adequate discussion
and subsequent document of
reproductive health counseling is
imperative in this at-risk population.
Federal surveillance systems
have the potential to improve
rates of contraceptive provision
and mitigate potential adverse
effects of teratogenic drugs. Our
findings strengthen the evidence
by describing an increase in
documentation of contraceptive
provision in this subgroup. However,
in our study, adolescents prescribed
teratogens associated with federal
surveillance systems were less
likely to have documentation of
sexual and menstrual histories.
This finding was unexpected given
that the focus of these systems is
to proactively reduce the risk of
unplanned pregnancy during drug
treatment. Simply, the availability
of these systems would seemingly
prompt the prescriber to actively
engage in contraceptive provision.
Our findings also illustrate that in
a large study cohort, contraceptive
provision (in its broadest sense) does
not appear to be documented and,
therefore, is not likely adequately
addressed by health care providers.

Potential reasons for this are many
(eg, fear or bias associated with
the assessment of menstrual or
sexual history in young adolescents,
inadequate knowledge regarding
teratogenic risks, concern over
identifying a positive risk behavior,
inadequate knowledge of adolescent
reproductive health best practices,
especially among subspecialists).
For example, a recent study reported
that time constraints, confidentiality
issues, and comfort level were cited
by health care providers as major
limitations to providing sexual health
care to adolescents in an emergency
department setting.14 Despite these
barriers, it is our contention that
failure to document a sexual history
for an adolescent who is prescribed
a medication that carries a high risk
of fetal harm should pregnancy occur
is unacceptable. In the recent policy
statement, the American Academy
of Pediatrics urged pediatricians
to “conduct a developmentallytargeted sexual history … and
provide appropriate screening and/
or education about safe and effective
contraceptive methods.”15 The
statement also urged pediatricians to
be familiar with counseling, insertion,
and/or referral for long-acting
reversible contraceptive options (eg,
implant and intrauterine device).
These recommendations underscore
the role of the pediatrician,
both primary care provider
and subspecialist, in promoting
optimal reproductive health care
to adolescents, particularly those
prescribed medications with known
teratogenic potential.
Our study used the FDA pregnancy
risk category D or X to classify
medications with evidence of
teratogenic potential. However,
this current classification
system has been criticized for its
oversimplification of complicated
information regarding risks and
benefits of using medications during
pregnancy and lack of inclusion of
discussion for use in patients of
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reproductive potential. To address
this long-standing concern expressed
by clinicians and scientists, the FDA
recently developed the pregnancy
and lactation labeling final rule
(PLLR), which was published in
December 2014. The PLLR will
abolish the current pregnancy risk
category designation (A, B, C, D, or
X) and incorporate a monograph
with discussion of current evidence
regarding safety in not only
pregnancy and lactation but also in
patients of reproductive potential.
The reproductive health subsection
will include “information, when
necessary, about the need for
pregnancy testing, contraception
recommendations, and information
about infertility as it relates to
the drug.”16 This change will
provide prescribers more detailed
information (ie, “talking points”)
regarding risks versus benefits of
these medications when prescribed
to adolescents of reproductive
potential. After full incorporation
into the PLLR, the teratogenic
medications chosen for this analysis
will carry more comprehensive
information based on available
evidence to aid in future reproductive
health counseling.
A few caveats are important to note
when interpreting the findings of our
study. The retrospective approach
involves inherent limitations;
however, this design was chosen
because it was the most appropriate

methodology to accomplish our
initial inquiry and, specifically, to
determine if a problem existed with
regard to the prescribing of potential
teratogens. The data captured in this
study are, by their nature, limited
to documentation by providers.
For example, the automated key
search terms with >1 meaning,
such as “implant” and “sex,” had the
potential to confound our findings.
Modifying these 2 terms within the
automated key term search method
via discrete definition would likely
further improve specificity, as well as
positive predictive value of the novel
method used to query our medical
records. Accordingly, it is possible
that verbal contraceptive provision
was provided but was not adequately
recorded in the EMR. Finally, our
study did not identify and exclude
patients with developmental delay or
significant cognitive impairment who
may have a more limited need for
contraceptive provision based on the
severity of their neurologic deficit.

CONCLUSIONS
Documentation of contraceptive
provision among female adolescents
prescribed teratogens by pediatric
providers is low; only 28.6% of
study participants received this
critical care. Opportunity exists
in these adolescents to increase
rates of contraceptive counsel, the
prescription of contraception if

appropriate, or referral for such
care when it becomes necessary
to use a medication with known
teratogenic potential. Female
adolescents and their parents
should be educated regarding the
teratogenic risk of the medications
prescribed to them and counseled
on safe and effective reproductive
choices. These prescriber-patient
interventions should be adequately
documented in the medical record.
Prescriber education is also
warranted to increase knowledge of
commonly prescribed medications
and systems/approaches currently
available to mitigate their potential
serious adverse effects, including
teratogenicity. Further studies
evaluating the efficacy of such
interventions, both educational and
systems based, are warranted.
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